NCI launching Pediatric MATCH trial

NCI and the Children’s Oncology Group (COG) began the Phase II NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) to determine whether cancer therapies can be targeted effectively to a predefined set of genetic mutations independent of cancer type or site.

The study is a pediatric counterpart to the Phase II basket study NCI-MATCH, which the NCI's National Clinical Trials Network (NCTN) began in 2015. COG is part of the NCTN (see BioCentury, June 8, 2015 & BioCentury Extra, June 1, 2015)...